# Phunware, Inc.: financial statements, quarterly

PHUN · Nasdaq · CIK 1665300 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/phun.md) · [Financials](/companies/phun/financials.md) · [Filings](/companies/phun/filings.md) · [Insiders](/companies/phun/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/phun/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.3](/filings/0000950170-24-124197.md) | [0.9 d](/filings/0000950170-25-047919.md) | [0.9](/filings/0000950170-25-072874.md) | [1.0](/filings/0000950170-25-105877.md) | [0.7](/filings/0001193125-25-272407.md) | [0.6 d](/filings/0001193125-26-126850.md) | [0.7](/filings/0001193125-26-216740.md) | [0.5](/filings/0001193125-26-342349.md) | [0.6](/filings/0001193125-25-272407.md) | [0.8 d](/filings/0001193125-26-126850.md) | [0.5](/filings/0001193125-26-216740.md) | [0.8](/filings/0001193125-26-342349.md) |
| Cost of revenue | $m | [0.6](/filings/0000950170-24-124197.md) | [0.5 d](/filings/0000950170-25-047919.md) | [0.4](/filings/0000950170-25-072874.md) | [0.5](/filings/0000950170-25-105877.md) | [0.3](/filings/0001193125-25-272407.md) | [0.5 d](/filings/0001193125-26-126850.md) | [0.3](/filings/0001193125-26-216740.md) | [0.3](/filings/0001193125-26-342349.md) | [0.3](/filings/0001193125-25-272407.md) | [0.3 d](/filings/0001193125-26-126850.md) | [0.2](/filings/0001193125-26-216740.md) | [0.2](/filings/0001193125-26-342349.md) |
| Gross profit | $m | [0.6](/filings/0000950170-24-124197.md) | [0.4 d](/filings/0000950170-25-047919.md) | [0.5](/filings/0000950170-25-072874.md) | [0.5](/filings/0000950170-25-105877.md) | [0.3](/filings/0001193125-25-272407.md) | [0.1 d](/filings/0001193125-26-126850.md) | [0.4](/filings/0001193125-26-216740.md) | [0.2](/filings/0001193125-26-342349.md) | [0.3](/filings/0001193125-25-272407.md) | [0.5 d](/filings/0001193125-26-126850.md) | [0.4](/filings/0001193125-26-216740.md) | [0.6](/filings/0001193125-26-342349.md) |
| Research and development | $m | [1.0](/filings/0000950170-24-124197.md) | [0.4 d](/filings/0000950170-25-047919.md) | [0.5](/filings/0000950170-25-072874.md) | [0.5](/filings/0000950170-25-105877.md) | [0.6](/filings/0001193125-25-272407.md) | [0.7 d](/filings/0001193125-26-126850.md) | [0.8](/filings/0001193125-26-216740.md) | [1.0](/filings/0001193125-26-342349.md) | [0.7](/filings/0001193125-25-272407.md) | [0.7 d](/filings/0001193125-26-126850.md) | [0.9](/filings/0001193125-26-216740.md) | [1.5](/filings/0001193125-26-342349.md) |
| Operating income | $m | [(13.3)](/filings/0000950170-24-124197.md) | [(19.6) d](/filings/0000950170-25-047919.md) | [(2.9)](/filings/0000950170-25-072874.md) | [(2.9)](/filings/0000950170-25-105877.md) | [(3.2)](/filings/0001193125-25-272407.md) | [(4.9) d](/filings/0001193125-26-126850.md) | [(4.8)](/filings/0001193125-26-216740.md) | [(4.3)](/filings/0001193125-26-342349.md) | [(3.5)](/filings/0001193125-25-272407.md) | [(7.9) d](/filings/0001193125-26-126850.md) | [(4.0)](/filings/0001193125-26-216740.md) | [(6.0)](/filings/0001193125-26-342349.md) |
| Interest expense | $m | [0.3](/filings/0000950170-24-124197.md) | [0.4 d](/filings/0000950170-25-047919.md) | [0.1](/filings/0001628280-24-022743.md) | [0.0](/filings/0001493152-24-031015.md) | [0.0](/filings/0000950170-24-124197.md) | [0.0 d](/filings/0000950170-25-047919.md) | [0.0](/filings/0001193125-26-216740.md) | [0.0](/filings/0001193125-26-342349.md) | [0.0](/filings/0001193125-25-272407.md) | [0.0 d](/filings/0001193125-26-126850.md) | [0.0](/filings/0001193125-26-216740.md) | [0.0](/filings/0001193125-26-342349.md) |
| Income tax | $m | [0.0](/filings/0001628280-23-038352.md) | [0.0 d](/filings/0000950170-25-047919.md) | [0.0](/filings/0000950170-25-072874.md) | [0.0](/filings/0000950170-25-105877.md) | [0.0](/filings/0001193125-25-272407.md) | [0.0 d](/filings/0001193125-26-126850.md) | [0.0](/filings/0001193125-26-216740.md) | [0.0](/filings/0001193125-26-342349.md) | [0.0](/filings/0001193125-25-272407.md) | [(0.0) d](/filings/0001193125-26-126850.md) | [0.0](/filings/0001193125-26-216740.md) | [0.0](/filings/0001193125-26-342349.md) |
| Net income | $m | [(19.0)](/filings/0000950170-24-124197.md) | [(23.0) d](/filings/0000950170-25-047919.md) | [(2.3)](/filings/0000950170-25-072874.md) | [(2.6)](/filings/0000950170-25-105877.md) | [(2.8)](/filings/0001193125-25-272407.md) | [(2.6) d](/filings/0001193125-26-126850.md) | [(3.7)](/filings/0001193125-26-216740.md) | [(3.1)](/filings/0001193125-26-342349.md) | [(2.4)](/filings/0001193125-25-272407.md) | [(2.1) d](/filings/0001193125-26-126850.md) | [(3.2)](/filings/0001193125-26-216740.md) | [(5.2)](/filings/0001193125-26-342349.md) |
| Diluted EPS | $ per share | [(0.16)](/filings/0001628280-23-038352.md) | not reported | [(0.33)](/filings/0000950170-25-072874.md) | [(0.32)](/filings/0000950170-25-105877.md) | [(0.25)](/filings/0001193125-25-272407.md) | not reported | [(0.18)](/filings/0001193125-26-216740.md) | [(0.16)](/filings/0001193125-26-342349.md) | [(0.12)](/filings/0001193125-25-272407.md) | not reported | [(0.16)](/filings/0001193125-26-216740.md) | [(0.26)](/filings/0001193125-26-342349.md) |
| Basic EPS | $ per share | [(0.16)](/filings/0001628280-23-038352.md) | not reported | [(0.33)](/filings/0000950170-25-072874.md) | [(0.32)](/filings/0000950170-25-105877.md) | [(0.25)](/filings/0001193125-25-272407.md) | not reported | [(0.18)](/filings/0001193125-26-216740.md) | [(0.16)](/filings/0001193125-26-342349.md) | [(0.12)](/filings/0001193125-25-272407.md) | not reported | [(0.16)](/filings/0001193125-26-216740.md) | [(0.26)](/filings/0001193125-26-342349.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [2.9](/filings/0001628280-23-038352.md) | [3.9](/filings/0000950170-25-047919.md) | [21.6](/filings/0001628280-24-022743.md) | [20.4](/filings/0001493152-24-031015.md) | [35.5](/filings/0000950170-24-124197.md) | [113](/filings/0001193125-26-126850.md) | [110](/filings/0000950170-25-072874.md) | [106](/filings/0000950170-25-105877.md) | [104](/filings/0001193125-25-272407.md) | [101](/filings/0001193125-26-342349.md) | [97.9](/filings/0001193125-26-216740.md) | [92.1](/filings/0001193125-26-342349.md) |
| Current assets | $m | [5.5](/filings/0001628280-23-038352.md) | [5.0](/filings/0000950170-25-047919.md) | [22.6](/filings/0001628280-24-022743.md) | [21.7](/filings/0001493152-24-031015.md) | [39.8](/filings/0000950170-24-124197.md) | [114](/filings/0001193125-26-126850.md) | [111](/filings/0000950170-25-072874.md) | [107](/filings/0000950170-25-105877.md) | [105](/filings/0001193125-25-272407.md) | [120](/filings/0001193125-26-342349.md) | [99.1](/filings/0001193125-26-216740.md) | [93.0](/filings/0001193125-26-342349.md) |
| Total assets | $m | [27.8](/filings/0001628280-23-038352.md) | [6.7](/filings/0000950170-25-047919.md) | [24.3](/filings/0001628280-24-022743.md) | [23.1](/filings/0001493152-24-031015.md) | [41.0](/filings/0000950170-24-124197.md) | [115](/filings/0001193125-26-126850.md) | [112](/filings/0000950170-25-072874.md) | [108](/filings/0000950170-25-105877.md) | [106](/filings/0001193125-25-272407.md) | [121](/filings/0001193125-26-342349.md) | [99.7](/filings/0001193125-26-216740.md) | [93.5](/filings/0001193125-26-342349.md) |
| Current liabilities | $m | [18.2](/filings/0001628280-23-038352.md) | [16.5](/filings/0000950170-25-047919.md) | [8.2](/filings/0001628280-24-022743.md) | [7.7](/filings/0001493152-24-031015.md) | [10.5](/filings/0000950170-24-124197.md) | [6.5](/filings/0001193125-26-126850.md) | [7.2](/filings/0000950170-25-072874.md) | [6.2](/filings/0000950170-25-105877.md) | [6.2](/filings/0001193125-25-272407.md) | [23.9](/filings/0001193125-26-342349.md) | [5.8](/filings/0001193125-26-216740.md) | [4.7](/filings/0001193125-26-342349.md) |
| Total liabilities | $m | [21.3](/filings/0001628280-23-038352.md) | [18.2](/filings/0000950170-25-047919.md) | [9.6](/filings/0001628280-24-022743.md) | [9.0](/filings/0001493152-24-031015.md) | [11.9](/filings/0000950170-24-124197.md) | [7.6](/filings/0001193125-26-126850.md) | [8.4](/filings/0000950170-25-072874.md) | [7.5](/filings/0000950170-25-105877.md) | [7.3](/filings/0001193125-25-272407.md) | [24.6](/filings/0001193125-26-342349.md) | [6.5](/filings/0001193125-26-216740.md) | [5.0](/filings/0001193125-26-342349.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | [5.6](/filings/0001628280-23-038352.md) | [4.9](/filings/0000950170-25-047919.md) | [0.0](/filings/0001628280-24-022743.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [6.6](/filings/0000950170-24-124197.md) | [(11.5)](/filings/0001193125-26-126850.md) | [14.6](/filings/0000950170-25-105877.md) | [14.1](/filings/0001193125-25-272407.md) | [29.1](/filings/0001193125-25-272407.md) | [107](/filings/0001193125-26-342349.md) | [104](/filings/0001193125-26-342349.md) | [101](/filings/0001193125-26-342349.md) | [98.3](/filings/0001193125-25-272407.md) | [96.3](/filings/0001193125-26-342349.md) | [93.2](/filings/0001193125-26-342349.md) | [88.5](/filings/0001193125-26-342349.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(3,309) d](/filings/0000950170-24-124197.md) | [(2,566) d](/filings/0000950170-25-047919.md) | [(5,530)](/filings/0000950170-25-072874.md) | [(2,675) d](/filings/0000950170-25-105877.md) | [(2,385) d](/filings/0001193125-25-272407.md) | [(2,712) d](/filings/0001193125-26-126850.md) | [(3,335)](/filings/0001193125-26-216740.md) | [(3,455) d](/filings/0001193125-26-342349.md) | [(2,481) d](/filings/0001193125-25-272407.md) | [(3,196) d](/filings/0001193125-26-126850.md) | [(2,727)](/filings/0001193125-26-216740.md) | [(5,727) d](/filings/0001193125-26-342349.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001628280-23-038352.md) | [0.0 d](/filings/0001628280-24-011484.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $k | [0.0 d](/filings/0001628280-23-038352.md) | [0.0 d](/filings/0001628280-24-011484.md) | [0.0](/filings/0001628280-24-022743.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [98.8](/filings/0001628280-23-038352.md) | [2,063](/filings/0001628280-24-022743.md) | [2.1](/filings/0001493152-24-031015.md) | [2.4](/filings/0000950170-24-124197.md) | [6.9](/filings/0000950170-25-072874.md) | [8.3](/filings/0000950170-25-105877.md) | [11.1](/filings/0001193125-25-272407.md) | [20.2](/filings/0001193125-26-216740.md) | [20.2](/filings/0001193125-26-342349.md) | [20.2](/filings/0001193125-25-272407.md) | [20.2](/filings/0001193125-26-216740.md) | [20.4](/filings/0001193125-26-342349.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 20,462,675 at 2026-08-05, from the cover of the [10-Q filed 2026-08-10](/filings/0001193125-26-342349.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.